Cilicant: Advancing drug stability through active packaging science

Manish Jain, MD, CILICANT elaborates how his company is pioneering the shift from passive to active pharma packaging, combining innovation and sustainability to enhance drug stability and patient safety. With a mission rooted in purposeful protection, the company is shaping the future of packaging through science, collaboration, and responsible design

- 

Packaging's new role in pharma

In my experience in the phar maceutical packaging industry, one thing has become increasingly clear: packaging is no longer a passive layer. It is an active participant in ensuring product integrity. The medicines we make today are more sensitive, the supply chains more complex, and the expectations for patient safety higher than ever.

At CILICANT, our focus has always been on one idea-protection. Protecting the stability of formulations, protecting the trust of patients, and protecting the promise that every dose delivers. This belief shapes the way we innovate, how we collaborate, and the way we see our role in the larger healthcare ecosystem.

The industry we serve operates in a space where even a minor lapse can alter outcomes. That is why our pursuit of excellence is constant and deliberate. Active packaging, when done right, bridges science and assurance - it is the invisible layer that safeguards efficacy, consistency, and confidence.

Innovation with purpose

The pace of pharmaceutical innovation is relentless. As formulations evolve, so must packaging. Our R&D team spends a lot of time not just creating new products, but understanding what challenges our partners are facing at various stages on the manufacturing floor, during stability testing, and across distribution chains that span varied climates.